Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial

DSMB approval to proceed to second cohort of REGALS trial (T Regulatory Cells for ALS). Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803 (Neurotrophic T regulatory cells) HOUSTON, Feb. 19, 2024 /PRNewswire/ — Cellenkos® today announced encouraging safety data from its…